The FDA has approved Phesgo™ (pertuzumab, trastuzumab, hyaluronidase-zzxf; Genentech), in combination with chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.

The FDA said it has approved an injection called Phesgo that can treat adults with HER2-positive breast cancer at home. HER2-positive breast cancer makes up about one-fifth of breast cancers.

Five trastuzumab biosimilars have been approved in the United States for HER2-positive breast cancer as of late 2019: trastuzumab-anns, trastuzumab-qyyp, trastuzumab-dttb, trastuzumab-pkrb, and ...

Patients with HER2-positive breast cancer that has spread to other parts of their body live around 16 months longer if treated with a combination of pertuzumab, trastuzumab and chemotherapy ...

The combination of pertuzumab and trastuzumab had superior antitumor activity in women with early HER2-positive breast cancer, according to Phase II study results of the NeoSphere neoadjuvant trial.

APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease–free survival (IDFS) (hazard ratio 0.81 [95% CI, ...

CHICAGO — Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus trastuzumab and pertuzumab across patients with HER2-positive ...

The approval of pertuzumab in free and fixed combination with trastuzumab includes the adjuvant (supportive) therapy of patients with HER2-positive early breast cancer at high risk of recurrence.

In the landmark CLEOPATRA study (NCT00567190), THP significantly improved median overall survival (OS) from 40.8 months (95% CI, 35.8-48.3) with placebo, trastuzumab, and docetaxel to 56.5 months ...

Topline results were announced from a phase 3 trial evaluating fam-trastuzumab deruxtecan-nxki in combination with pertuzumab as a first-line treatment for patients with human epidermal growth ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated ...